Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive DisorderGlobeNewsWire • 12/01/20
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization™ PlatformBusiness Wire • 11/04/20
Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer's Disease Agitation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire • 11/03/20
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 10/28/20
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules CapitalGlobeNewsWire • 09/29/20
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of MigraineGlobeNewsWire • 09/24/20
Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 09/21/20
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy MeetingGlobeNewsWire • 09/21/20
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured PresentationGlobeNewsWire • 09/17/20
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive DisorderGlobeNewsWire • 09/14/20
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology CongressGlobeNewsWire • 09/10/20
Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/09/20
Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy MeetingGlobeNewsWire • 08/31/20
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual MeetingGlobeNewsWire • 08/28/20
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of MigraineGlobeNewsWire • 08/20/20